Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7/ADR cells and xenograft models

Acquired resistance to chemo-drugs remains a major obstacle to successful cancer therapy. Metformin, a well-documented drug for treating type II diabetes, was recently proposed as a novel agent for tumor treatment. In this study, we found that metformin suppressed MCF7/ADR, a doxorubicin-resistant b...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Wang, Meng, Zhi, Pei, You, Jian, Gao, Jian-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788630/
https://www.ncbi.nlm.nih.gov/pubmed/29416762
http://dx.doi.org/10.18632/oncotarget.23187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788630/
https://www.ncbi.nlm.nih.gov/pubmed/29416762
http://dx.doi.org/10.18632/oncotarget.23187

Ejemplares similares